Literature DB >> 19267246

The silent mutation nucleotide 744 G --> A, Lys172Lys, in exon 6 of BRCA2 results in exon skipping.

Thomas V O Hansen1, Ane Y Steffensen, Lars Jønson, Mette K Andersen, Bent Ejlertsen, Finn C Nielsen.   

Abstract

Germ-line mutations in BRCA2 predispose to breast and ovarian cancer. Mutations are widespread throughout the gene and include disease-causing mutations as frameshift, nonsense, splicing mutations and large genomic rearrangements. However a large number of mutations, including missense, silent and intron variants are of unknown significance. Here, we describe the functional characterization of a silent mutation (nucleotide 744 G --> A/c.516 G --> A, Lys172Lys) in exon 6 of BRCA2 in a Danish family with breast and ovarian cancer. Exon trapping analysis showed that the mutation results in skipping of exon 6 and/or both exon 5 and 6, which was verified by RT-PCR analysis on RNA isolated from whole blood of the affected patient. We therefore conclude that the BRCA2 silent mutation Lys172Lys is a disease-causing mutation.

Entities:  

Mesh:

Year:  2009        PMID: 19267246     DOI: 10.1007/s10549-009-0359-4

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  14 in total

1.  Prophylactic total gastrectomy in hereditary diffuse gastric cancer: identification of two novel CDH1 gene mutations-a clinical observational study.

Authors:  Linda Bardram; Thomas V O Hansen; Anne-Marie Gerdes; Susanne Timshel; Lennart Friis-Hansen; Birgitte Federspiel
Journal:  Fam Cancer       Date:  2014-06       Impact factor: 2.375

2.  Screening of 1331 Danish breast and/or ovarian cancer families identified 40 novel BRCA1 and BRCA2 mutations.

Authors:  Thomas V O Hansen; Lars Jønson; Ane Y Steffensen; Mette K Andersen; Susanne Kjaergaard; Anne-Marie Gerdes; Bent Ejlertsen; Finn C Nielsen
Journal:  Fam Cancer       Date:  2011-06       Impact factor: 2.375

3.  Double germline mutations in APC and BRCA2 in an individual with a pancreatic tumor.

Authors:  Caroline Goehringer; Christian Sutter; Matthias Kloor; Johannes Gebert; Emily P Slater; Monika Keller; Irmgard Treiber; Petra Ganschow; Martina Kadmon; Ute Moog
Journal:  Fam Cancer       Date:  2017-04       Impact factor: 2.375

Review 4.  BRCA1-No Matter How You Splice It.

Authors:  Dan Li; Lisa M Harlan-Williams; Easwari Kumaraswamy; Roy A Jensen
Journal:  Cancer Res       Date:  2019-04-16       Impact factor: 12.701

5.  Inferring Potential Cancer Driving Synonymous Variants.

Authors:  Zishuo Zeng; Yana Bromberg
Journal:  Genes (Basel)       Date:  2022-04-27       Impact factor: 4.141

Review 6.  Synonymous Variants: Necessary Nuance in Our Understanding of Cancer Drivers and Treatment Outcomes.

Authors:  Nayiri M Kaissarian; Douglas Meyer; Chava Kimchi-Sarfaty
Journal:  J Natl Cancer Inst       Date:  2022-08-08       Impact factor: 11.816

7.  Identification of a Danish breast/ovarian cancer family double heterozygote for BRCA1 and BRCA2 mutations.

Authors:  Ane Y Steffensen; Lars Jønson; Bent Ejlertsen; Anne-Marie Gerdes; Finn C Nielsen; Thomas V O Hansen
Journal:  Fam Cancer       Date:  2010-09       Impact factor: 2.375

8.  BRCA1 c.4987-3C>G is a pathogenic mutation.

Authors:  Rita D Brandão; Kees E P van Roozendaal; Demis Tserpelis; Beppy Caanen; Encarna Gómez García; Marinus J Blok
Journal:  Breast Cancer Res Treat       Date:  2011-11-24       Impact factor: 4.872

9.  First report of molecular diagnosis of Tunisian hemophiliacs A: identification of 8 novel causative mutations.

Authors:  Hejer Elmahmoudi; Houssein Khodjet-el-khil; Edvard Wigren; Asma Jlizi; Kaouther Zahra; Dorothé Pellechia; Christine Vinciguerra; Balkis Meddeb; Amel Ben Ammar Elggaaied; Emna Gouider
Journal:  Diagn Pathol       Date:  2012-08-10       Impact factor: 2.644

10.  Functional examination of MLH1, MSH2, and MSH6 intronic mutations identified in Danish colorectal cancer patients.

Authors:  Sanne M Petersen; Mette Dandanell; Lene J Rasmussen; Anne-Marie Gerdes; Lotte N Krogh; Inge Bernstein; Henrik Okkels; Friedrik Wikman; Finn C Nielsen; Thomas V O Hansen
Journal:  BMC Med Genet       Date:  2013-10-03       Impact factor: 2.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.